When we gave the call of this R&D focused company engaged in the manufacture of enzymes and probiotics, the company had Covid-related challenges but showed promise of growth. It was later also pulled down by consolidation of acquisitions and costs related to new product launches. We therefore knew that the call would take longer to pay off. The stock went through a significant correction after our initial recommendation as earnings disappointed.
PrimeInvestor Raises Funding from Rainmatter to Scale Portfolio Management Services
PrimeInvestor Desk
April 22, 2026
Read More »
